Complications in clotting
Find out how haemophilia can dramatically impact the lives of people with the disorder DownloadMore
Haemophilia A is the most common type of haemophilia, affecting approximately 900,000 people around the world.2 People with haemophilia A either lack or have low levels of an essential protein known as factor VIII that plays a crucial role in blood clotting.
When a bleed occurs in a healthy person, factor VIII binds to factors IXa and X, which are critical steps in the formation of a blood clot and help stop bleeding. However, in a person with haemophilia A, the lack or decrease of factor VIII interrupts this process and affects the ability to form a clot. These bleeds can present a significant health concern as they often cause pain and can lead to chronic swelling, deformity, reduced mobility, and long-term joint damage.3 In addition to impacting a person’s quality of life,4 these bleeds can be life threatening if they go into vital organs, such as the brain.5,6
For more than 20 years, Roche has been innovating and delivering medicines for people with diseases of the blood. With the rise of novel therapies within haemophilia, we are working closely with all corners of the global haemophilia community – through our efforts to help improve the provision of treatments for those who need it most; through our dedication towards supporting patients at all stages of their haemophilia journey; and ultimately helping to transform the way haemophilia is treated and managed.
Roche is consistently striving to be a trusted member of the haemophilia community, transforming the treatment landscape to help all people with haemophilia A live their best lives.